Effectiveness of empagliflozin in reducing hypoglycemic events as compared to sulfonylurea in type 2 diabetes patients during fasting in Ramadan: a single-center study Authors: Zareen Kiran, Nazish Fatima, Akhtar Ali Baloch, Khalil Ullah Shabbir Shaikh, Syed Muhammad Hasan, Muhammad Umar Khan Published: 2025 ABSTRACT BackgroundThis study aimed to compare the reduction in hospital admissions due to hypoglycemia and the decrease in HbA1c levels between empagliflozin and sulfonylurea, alongside the standard care provided to patients with type 2 diabetes during fasting.MethodologyA single-center prospective observational cohort study was conducted from March to June 2022. Patients were treated with stable doses of empagliflozin, sulfonylureas, metformin, and DPP-4 inhibitors at least two months before fasting. Stability was defined as unchanged doses for at least one month. Participants’ BMI distribution and treatment regimens were clarified. The eGFR cutoff of < 60 ml/min/1.73 m² was chosen based on international standards for renal function in diabetes.ResultsFemales were in the majority (60.3%) in the intervention (case) group. Most had ages ranging from 41 to 60 years; the empagliflozin group reported slightly fewer hypoglycemic events (26.5%) compared to the sulfonylurea group (31%), and both groups demonstrated statistically significant reductions in HbA1c levels (p < 0.0001), with a similar mean decrease of approximately 0.5%, during fasting, without changes in baseline antidiabetic medications. An odds ratio of 0.387 indicated a trend toward further HbA1c reduction with increasing empagliflozin dose. However, differences in baseline weight between groups may have influenced outcomes. Separate data for modern versus conventional sulfonylureas were analyzed, showing consistency in hypoglycemic event rates across both types.ConclusionsEmpagliflozin is effective for type 2 diabetic patients during Ramadan fasting in modestly reducing the hypoglycemic events requiring hospital admissions. While both empagliflozin and sulfonylureas led to comparable reductions in HbA1c, larger, controlled studies are warranted to further evaluate clinical outcomes and control for baseline differences.Clinical trial numberNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12902-025-02134-5. Background The holy month of Ramadan is the ninth month of the Islamic calendar. Muslims around the world observe fasting during this month, regardless of the season it occurs in or the region they belong to [1]. There are several risks of fasting in patients with diabetes, including diabetic ketoacidosis (DKA), hyperglycemia, dehydration, hypoglycemia (blood sugar levels below 70 mg/dl at any time during the 24-hour period while fasting in Ramadan), and thrombosis — often as a consequence of withholding or delaying medications, reduced fluid intake, or underlying illness — rather than fasting itself being the sole cause of these complications [2]. Dehydration is a greater concern in hot climates, especially in South Asia, which has a Muslim-majority [2]. Hence, Ramadan is considered a challenging time for the practicing physicians, diabetologists, and endocrinologists all over the world to address the hypoglycemic events or other diabetic complications in diabetic patients during fasting [3]. Numerous clinical trials have assessed the safety of various pharmacological treatments for diabetic patients observing Ramadan fasting [4]. Practical guidelines from the International Diabetes Federation and Diabetes and Ramadan (IDF-DAR) have provided essential direction for managing diabetes during this period [5]. Recent recommendations, including those from the IDF-DAR and the South Asian Diabetes Federation, underscore the safe use of newer antidiabetic agents such as SGLT-2 inhibitors, particularly empagliflozin [6, 7]. The Ramadan Study Group (2021), along with other regional studies, has emphasized individualized treatment strategies to optimize diabetes management during fasting [4, 8, 9]. However, with the evolution of newer anti-diabetic drugs prevailing in clinical practice, more clarification regarding safe fasting is desired in different parts of the world [10]. Sodium-glucose co-transporter 2 inhibitors (SGLT-2 inhibitors), particularly empagliflozin, have demonstrated significant cardio-renal benefits in clinical trials [11]. Moreover, compared to sulfonylureas, SGLT-2-I has been shown to cause less hypoglycemia [12]. Recently, the use of empagliflozin has become popular in Pakistan during fasting. However, sulfonylureas are still more commonly used in Pakistan because of their cheaper cost. As Ramadan is observed in summer this year; in the light of varying temperatures and use of this new drug in a treatment naïve population makes it prudent to understand the role of empagliflozin in controlling diabetes as well as whether it is safe and effective. The aim of this study was to compare the risk of hypoglycemia between empagliflozin and sulfonylurea during fasting in Ramadan, alongside the standard care provided to type 2 diabetic (T2DM) patients. The primary outcome was to assess the number of hypoglycemic events leading to hospital admission with empagliflozin versus sulfonylurea. Secondary outcomes included evaluating the reduction in HbA1c, the number of diabetic ketoacidosis events, urinary tract infections, decline in estimated glomerular filtration rate (eGFR), and occurrences of extreme dehydration, volume depletion, or low blood pressure with empagliflozin compared to sulfonylureas. Additionally, the rationale for combining sulfonylureas (modern and conventional) was scrutinized to provide clarity. Methodology Study design This single-center, prospective observational cohort study was conducted at the National Institute of Diabetes and Endocrinology, Dow University Hospital in Karachi, Pakistan, within the outpatient department, from March to June 2022. (With an average atmospheric temperature between 32 and 38 °C), after ethical approval from the institutional review board. The study period was designed from four weeks before Ramadan (according to Holy calendar, depending on citation of Moon) until four weeks post-Ramadan. Sample size The sample size was determined using OpenEpi, version 3, an open-source calculator, with a 95% confidence interval, margin of error as 3%, percentage of hypoglycemia in patients on empagliflozin of 1.8% in a previous study [13] and attrition rate of 15%; the sample size of the current study was calculated to be 76 (in each group). Thereby, a total of 152 participants were enrolled. However due to non-response rate of the participants and lack of awareness some of them refused to take part in the study, therefore sample size was reduced to a total of 126 participants randomized into two groups with 58 participants in the control group and 68 participants in the study group (cases). Operational definitions Hypoglycemia A condition characterized by abnormally low levels of blood glucose (sugar), defined in this study as blood glucose levels below 70 mg/dL during fasting periods. Hospital admissions due to hypoglycemia Patients requiring hospitalization for severe hypoglycemic events that are clinically significant and necessitate medical intervention, leading to a documented hospital stay. Participant inclusion and exclusion criteria Patients with type 2 diabetes mellitus (T2DM) aged 18 to 65 years who planned to fast for at least 20 days during Ramadan according to local sehri (dawn) and iftar (dusk) timings, were included in the study. These patients were treated with stable doses of sulfonylureas (glimepiride, gliclazide, or glibenclamide) or Empagliflozin (10–25 mg) combined with metformin (maximum 2000 mg) and DPP-4 inhibitors (100 mg). Stable doses were defined as no adjustments for at least one month. Patients who were pregnant or breastfeeding, those with impaired renal function (estimated Glomerular Filtration Rate [eGFR] < 60 ml/min/1.73 m²), recurrent urinary tract infections, alanine transaminase levels greater than 2.5 times the upper normal limit, any type of malignancy, cardiovascular events within the last 90 days, individuals who were unwilling to fast, were being treated with insulin or therapies outside the specified treatment groups, had a recent history of severe hypoglycemia (requiring assistance, causing seizures, or leading to unconsciousness), experienced recurrent diabetic ketoacidosis (DKA), or had contraindications for fasting were excluded from the study. Informed consent was obtained from all eligible participants. The eGFR cutoff of < 60 ml/min/1.73 m² was selected based on standard recommendations, ensuring patient safety during Ramadan [2, 6]. Studies such as the EPIDIAR Study (2004) and the Ramadan Prospective Diabetes Study (RPDS, 2010) informed these criteria, highlighting the risks of hypoglycemia and dehydration during fasting periods [6, 14]. Patients were divided into two groups: the Group A, consisting of patients on sulfonylureas (glimepiride 1–6 mg, gliclazide 60–120 mg, or glibenclamide 5–10 mg) before and during the study, along with a maximum of 2000 mg of metformin and 100 mg of DPP-4 inhibitors (vildagliptin/sitagliptin); and Group B, which included patients taking empagliflozin (either 10 mg, 12.5 mg, or 25 mg) before and during the study, along with the same dosages of metformin and DPP-4 inhibitors. Both groups were enrolled at least one month prior to fasting. Clinical and laboratory data Data was collected from all participants at a baseline visit four weeks before Ramadan and during a follow-up visit four weeks after Ramadan. Patients were instructed to document their blood glucose levels at seven different times each week. Various variables were recorded for each patient using a predefined proforma, including demographic information such as age, gender, weight, height, and body mass index (BMI) based on World Health Organization (WHO) criteria with Asian cutoffs: Underweight: <18.5 kg/m², Normal: 18.5–23 kg/m², Overweight: 23–25 kg/m², Obese: >25 kg/m². Clinical data included the duration of type 2 diabetes, details on complications (nephropathy, neuropathy, and retinopathy), macrovascular complications (such as a history of ischemic heart disease or cerebrovascular disease), and measurements of systolic and diastolic blood pressure at baseline and four weeks post-Ramadan. Incidents of hypoglycemia and any adverse events were also recorded. Laboratory data was collected for HbA1c levels, serum electrolytes (including sodium, potassium, chloride, and bicarbonate), serum creatinine levels, and eGFR four weeks before and four weeks after Ramadan. Urinalysis and urine culture results were documented to check for any signs of infection. Statistical analysis Statistical analysis was performed using SPSS version 26 (IBM, Chicago, IL). Continuous and categorical variables, including age, disease duration, mean laboratory parameters, gender, and adverse events, were presented as frequencies and percentages and compared using the chi-squared test. Differences between groups were analyzed with an independent t-test, and a p-value of < 0.05 was considered significant. Results The majority of study participants were female, comprising 60.3% of the cases, while the control group had a higher percentage of males at 51.7%. Most participants were aged between 41 and 60 years, with 60.4% in the control group and 54.5% in the cases. In the control group, 46.6% had a normal BMI, 32.8% were classified as overweight, and 20.7% were obese. In the empagliflozin group, the distribution was different, with 19.1% having a normal BMI, 20.6% being overweight, and 60.3% categorized as obese. Additionally, a significant portion of the cases, 52.9%, had an average diabetes duration of three years or less. Comorbidities included hypertension, affecting 44.1% of participants in the cases and 24.1% in the control group. More details can be found in Tables 1 and 2. Table 1Baseline characteristics of the participants (n = 126)Baseline CharacteristicsControl(Group A on Sulphonylureas)Cases(Group B on Empagliflozin)N (%)N (%)GenderMales30 (51.7)26 (39.7)Females28 (48.3)39 (60.3)Age20 to 40 years11 (20.7)13 (19.1)41 to 60 years35 (60.4)37 (54.5)61 years and above11 (19)18 (26.5)Duration of Diabetes1 to 3 years20 (34.5)36 (52.9)4 to 9 years23 (39.6)20 (29.5)10 and above years15 (25.9)12 (17.6)ComorbiditiesHypertension (HTN)14 (24.1)30 (44.1)Retinopathy2 (3.4)4 (5.9)Dyslipidemia3 (5.2)7 (10.3)None39 (67.2)24 (35.3)Body Mass Index (BMI)aUnder weight0 (0)0 (0)Normal27 (46.6)13 (19.1)Over weight19 (32.8)14 (20.6)Obese12 (20.7)41 (60.3)a WHO criteria for overweight and obesity (Asian Cutoff) Table 1Baseline characteristics of the participants (n = 126)Baseline CharacteristicsControl(Group A on Sulphonylureas)Cases(Group B on Empagliflozin)N (%)N (%)GenderMales30 (51.7)26 (39.7)Females28 (48.3)39 (60.3)Age20 to 40 years11 (20.7)13 (19.1)41 to 60 years35 (60.4)37 (54.5)61 years and above11 (19)18 (26.5)Duration of Diabetes1 to 3 years20 (34.5)36 (52.9)4 to 9 years23 (39.6)20 (29.5)10 and above years15 (25.9)12 (17.6)ComorbiditiesHypertension (HTN)14 (24.1)30 (44.1)Retinopathy2 (3.4)4 (5.9)Dyslipidemia3 (5.2)7 (10.3)None39 (67.2)24 (35.3)Body Mass Index (BMI)aUnder weight0 (0)0 (0)Normal27 (46.6)13 (19.1)Over weight19 (32.8)14 (20.6)Obese12 (20.7)41 (60.3)a WHO criteria for overweight and obesity (Asian Cutoff) Baseline characteristics of the participants (n = 126) a WHO criteria for overweight and obesity (Asian Cutoff) Table 2Comparison of average blood pressure and laboratory parameters between both groupsBaseline CharacteristicsControl(Group A on Sulphonylureas)Cases(Group B on Empagliflozin)Blood Pressure (mmHg)*Systolic BP141.5 (20.0)134.4 (16.7)Diastolic BP81.0 (10.4)79.6 (10.5)HbA1c Levels*8.45 (1.8)8.4 (2.5)Creatinine (mg/dl)*0.84 (0.3)0.8 (0.3)eGFR (ml/min/1.73 m2)*80.3 (100.2)95.5 (32.1)*Data presented as Mean (SD) Table 2Comparison of average blood pressure and laboratory parameters between both groupsBaseline CharacteristicsControl(Group A on Sulphonylureas)Cases(Group B on Empagliflozin)Blood Pressure (mmHg)*Systolic BP141.5 (20.0)134.4 (16.7)Diastolic BP81.0 (10.4)79.6 (10.5)HbA1c Levels*8.45 (1.8)8.4 (2.5)Creatinine (mg/dl)*0.84 (0.3)0.8 (0.3)eGFR (ml/min/1.73 m2)*80.3 (100.2)95.5 (32.1)*Data presented as Mean (SD) Comparison of average blood pressure and laboratory parameters between both groups *Data presented as Mean (SD) The empagliflozin group had a slightly lower rate of hypoglycemia-related hospitalizations (26.5%) compared to the Sulfonylurea group (31%). However, this difference was not statistically significant based on Fisher’s Exact Test (p = > 0.3). When evaluating the safety of Empagliflozin, the incidence of diabetic ketoacidosis was significantly lower (P-value < 0.0001), as were urinary tract infections (P-value < 0.0001) and the decline in estimated glomerular filtration rate (eGFR) compared to Sulphonylureas (P-value = 0.048). Specifically, the Empagliflozin regimen led to a significantly reduced incidence of diabetic ketoacidosis (P-value < 0.0001). Interestingly, hospital admissions for dehydration were notably higher in the sulfonylurea group (31%) compared to the empagliflozin group (1.5%). While SGLT2 inhibitors like empagliflozin are known to increase diuresis, this finding may be attributed to unmeasured confounders such as baseline hydration status, differences in fluid intake, or reporting biases. Further clinical validation is needed. Furthermore, urinary tract infections were not reported significantly by patients (P-value < 0.0001) (see Table 3 for details). Table 3Safety of the drug empagliflozin as compared to sulfonylureas towards the patients of type 2 diabetes mellitus during fasting (n = 126)Safety VariablesControl(Group A on Sulphonylureas)Cases(Group B on Empagliflozin)P-valueN (%)N (%)Any hospital admission due to hypoglycemia?Yes18 (31)18 (26.5)> 0.3No40 (69)50 (73.5)Any hospital admission due to extreme dehydration and/or low blood pressure?Yes18 (31)1 (1.5)< 0.001No40 (69)67 (98.5)Any hospital admission due to the event of Diabetic Ketoacidosis (DKA)?Yes5 (8.6)0 (0)< 0.0001No53 (91.4)68 (100)Any symptom of Urinary tract infection (UTI) occurred?Yes19 (32.7)3 (4.4)< 0.0001No39 (67.2)65 (95.6)Systolic Blood Pressure (mmHg)*Pre intervention141.5 (20.0)134.4 (16.7)0.029Post intervention139.5 (20.7)129.6 (18.2)Diastolic Blood Pressure (mmHg)*Pre intervention81.1 (10.4)79.6 (10.5)0.253Post intervention76.4 (10.2)79.5 (9.2)Creatinine (mg/dl)*Pre intervention0.8 (0.3)0.8 (0.3)> 0.9Post intervention0.8 (0.3)0.8 (0.2)eGFR (ml/min/1.73m2)*Pre intervention80.4 (100.3)95.6 (32.1)0.048Post intervention79.0 (100.0)94.6 (32.4)*Data presented as Mean (SD) Table 3Safety of the drug empagliflozin as compared to sulfonylureas towards the patients of type 2 diabetes mellitus during fasting (n = 126)Safety VariablesControl(Group A on Sulphonylureas)Cases(Group B on Empagliflozin)P-valueN (%)N (%)Any hospital admission due to hypoglycemia?Yes18 (31)18 (26.5)> 0.3No40 (69)50 (73.5)Any hospital admission due to extreme dehydration and/or low blood pressure?Yes18 (31)1 (1.5)< 0.001No40 (69)67 (98.5)Any hospital admission due to the event of Diabetic Ketoacidosis (DKA)?Yes5 (8.6)0 (0)< 0.0001No53 (91.4)68 (100)Any symptom of Urinary tract infection (UTI) occurred?Yes19 (32.7)3 (4.4)< 0.0001No39 (67.2)65 (95.6)Systolic Blood Pressure (mmHg)*Pre intervention141.5 (20.0)134.4 (16.7)0.029Post intervention139.5 (20.7)129.6 (18.2)Diastolic Blood Pressure (mmHg)*Pre intervention81.1 (10.4)79.6 (10.5)0.253Post intervention76.4 (10.2)79.5 (9.2)Creatinine (mg/dl)*Pre intervention0.8 (0.3)0.8 (0.3)> 0.9Post intervention0.8 (0.3)0.8 (0.2)eGFR (ml/min/1.73m2)*Pre intervention80.4 (100.3)95.6 (32.1)0.048Post intervention79.0 (100.0)94.6 (32.4)*Data presented as Mean (SD) Safety of the drug empagliflozin as compared to sulfonylureas towards the patients of type 2 diabetes mellitus during fasting (n = 126) *Data presented as Mean (SD) In terms of efficacy, both groups experienced a statistically significant reduction in HbA1c from baseline (around 0.5%), likely because of prolonged fasting during Ramadan. However, the difference in HbA1c reduction between the groups was minimal and not statistically significant, indicating no clear superiority of empagliflozin over sulfonylureas in this aspect (P-value < 0.0001). The empagliflozin group had a pre-Ramadan HbA1c of 8.45 ± 2.2%, which decreased to 7.89 ± 1.8% post-Ramadan. In contrast, the sulfonylurea group had a pre-Ramadan HbA1c of 8.45 ± 1.8% and a post-Ramadan level of 7.94 ± 1.7%. The negative odds ratio of 0.387 suggests that increasing the dosage of empagliflozin would lead to reductions in HbA1c levels. (Refer to Table 4 for more details.) Table 4Efficacy of the drug empagliflozin in comparison to sulfonylureas on HbA1c levels (n = 126)RegimenHbA1c LevelsP-valueOdds Ratio (OR)Pre-RamadanPost RamadanControl(Group A on Sulphonylureas)8.45 (1.8)7.94 (1.7)< 0.0001RefCases(Group B on Empagliflozin)8.45 (2.2)7.89 (1.8)< 0.00010.387Data presented as Mean (SD) Table 4Efficacy of the drug empagliflozin in comparison to sulfonylureas on HbA1c levels (n = 126)RegimenHbA1c LevelsP-valueOdds Ratio (OR)Pre-RamadanPost RamadanControl(Group A on Sulphonylureas)8.45 (1.8)7.94 (1.7)< 0.0001RefCases(Group B on Empagliflozin)8.45 (2.2)7.89 (1.8)< 0.00010.387Data presented as Mean (SD) Efficacy of the drug empagliflozin in comparison to sulfonylureas on HbA1c levels (n = 126) Control (Group A on Sulphonylureas) Cases (Group B on Empagliflozin) Data presented as Mean (SD) Modern sulfonylureas, such as glimepiride and gliclazide, have been associated with lower rates of hypoglycemia compared to glibenclamide. This observation is supported by a combined analysis that demonstrates consistent outcomes across various subgroups, indicating the efficacy and safety of empagliflozin in managing blood glucose levels with a reduced risk of hypoglycemic events. Discussion This study aimed to compare the risk of hypoglycemic events leading to hospital admissions between empagliflozin and sulfonylureas during Ramadan fasting, in addition to evaluating glycemic outcomes such as HbA1c reduction (P-value < 0.0001). Our findings revealed that both empagliflozin and sulfonylureas led to comparable reductions in HbA1c levels, with mean decreases of approximately 0.5% in each group. This modest improvement is likely influenced more by the prolonged fasting hours during Ramadan than by differences in pharmacologic efficacy, particularly given that the baseline medications were unchanged, indicating that the observed HbA1c reduction was likely because of fasting rather than drug potency. These findings are consistent with previous studies that have reported similar HbA1c reductions with SGLT2 inhibitors compared to sulfonylureas or other oral antidiabetic agents during Ramadan. Similarly, Eid et al. (2021) and Shao et al. (2018) also reported that SGLT2 inhibitors were effective in maintaining glycemic control during Ramadan, but without demonstrating significantly superior HbA1c reductions over other agents [15, 16]. These results support the notion that while SGLT2 inhibitors are safe and effective during fasting, their HbA1c-lowering advantage during Ramadan may not be markedly greater than sulfonylureas, particularly when both are used as part of combination therapy and under dietary modifications induced by fasting. Discrepancies in baseline BMI likely influenced outcomes; hence, a weight-adjusted analysis was performed. Ramadan studies on modern sulfonylureas were reviewed, aligning with findings of reduced hypoglycemic risks [2, 17]. For instance, the CRATOS study (2017) evaluating canagliflozin found a comparable decrease in HbA1c among fasting patients with type 2 diabetes [5, 18]. Recently, a study was conducted at another local university, which also revealed that hypoglycemic symptoms were more common in the patients using sulfonylureas [19]. Further, it was also reported in the study that patients taking the empagliflozin regimen were also observed to have reduced HbA1c [19]. These findings align with the present study; however, it is important to note that the degree of HbA1c reduction was comparable between the two treatment groups. This suggests that while empagliflozin is effective and well-tolerated during fasting, its glycemic benefit in terms of HbA1c reduction may not be significantly superior to sulfonylureas within the context of Ramadan. Additionally, HbA1c offers significant insights into prolonged glucose regulation; its capacity to identify transient variations within the relatively brief study period may be constrained. Incorporating supplementary evaluations, such as frequent blood glucose monitoring or alternative glycemic indicators attuned to short-term alterations, may yield a more holistic assessment of treatment efficacy during Ramadan. Although some of the patients reported symptomatic episodes of hypoglycemia in the current study, it was noticed that most of them were from the control group as compared to cases. This finding is consistent with previous research, which found a lower risk of hypoglycemic events in type 2 diabetic patients when taking any SGLT2 inhibitors like empagliflozin in comparison to any other oral anti-diabetic agents (OAA) during fasting [5, 10, 15, 19]. Another recent study found a decreased rate of hypoglycemic events in diabetic patients who were taking SGLT2 inhibitors in combination with insulin in comparison to patients who were taking other oral anti-diabetic agents (OAA) in combination with insulin during fasting [16]. The steadiness of these results strongly suggested that the SGLT2 inhibitors have an insulin-independent mechanism of action, which is associated with decreased hypoglycemia risk when compared to sulfonylureas. It was considered that fasting in Ramadan, particularly this year in periods of hot weather and long fasts of approximately 15 to 16 h, might increase dehydration and thrombosis risk in type 2 diabetes patients. However, it was found that only one patient reported the event of dehydration while fasting in the empagliflozin group as compared to sulfonylureas, where 31% reported dehydration. The higher incidence of dehydration in the sulfonylurea group may be attributable to indirect effects such as hypoglycemia-induced reductions in oral intake, comorbid conditions, or variations in hydration habits. Conversely, patients on empagliflozin may have benefited from more explicit counseling on the need to increase fluid intake during non-fasting hours due to its osmotic diuretic properties. These educational efforts may have influenced their hydration behavior and contributed to the lower dehydration rate observed in that group. However, these findings should be interpreted with caution, as dehydration events were self-reported and not clinically verified, making them susceptible to recall bias. Moreover, the lack of standardized clinical assessment limits the reliability of these observations and highlights the need for objective hydration status monitoring in future studies. Further studies should assess the impact of patient counseling and adherence to hydration recommendations during fasting periods. Previous studies have reported that SGLT2 inhibitors induced dehydration in a range of 1.2% to 1.5% [20, 21]. In contrast to the current findings, three other studies [5, 15, 19] found that the SGLT2 inhibitors, like empagliflozin, had an increased number of dehydration cases in comparison with sulfonylureas. However, one more study reported no difference in dehydration events between both the SGLT2 inhibitor-taking group and patients taking sulfonylureas during fasting [15]. The contradiction of the results among the studies could be attributed to the variances in weather conditions of the study locations, study designs, fluid intake of the patient, and the working environment. There were several limitations to note. Firstly, the study was single-centered, which inherently restricts its scope. Additionally, certain clinical parameters, such as dehydration or volume depletion, blood glucose levels, and eGFR, were not clinically evaluated, potentially introducing recall and information biases. Furthermore, there was a notable difference in weight between the cases and controls, which may also influence the study’s outcomes and limit the generalizability of the findings. In general, the occurrence of urinary tract infections is well-documented in the previous literature due to dehydration and glycosuria. Whereas, the incidence of urinary tract infections was not reported at a significant level by the patients in this study (P-value = < 0.0001). Similar results have been concluded in previous research, where no genitourinary infections were reported in the cases [5, 10, 15]. However, a study conducted by Yousuf et al. reported that patients in the empagliflozin group discontinued their medication due to mycotic genital infections [19], which is similar to the results of other studies conducted previously [22, 23]. It is recommended to educate patients about maintaining proper hygiene and increased fluid intake to prevent genitourinary tract infections. Conclusion In conclusion, empagliflozin was proven to be effective and well tolerated for type 2 diabetic patients during fasting. It was associated with fewer hypoglycemia-related admissions and demonstrated a reduction in HbA1c levels. However, the extent of HbA1c reduction was comparable to that observed with sulfonylureas, suggesting similar glycemic efficacy within the short duration of the study. Notably, there were some limitations, including that it was a single-center study with a limited number of patients included and reliance on self-reported outcomes. Furthermore, HbA1c provides valuable insights into long-term glucose management; its ability to detect short-term fluctuations within the relatively brief duration of the study may be limited. Clinical evaluations of most of the parameters, like dehydration or volume depletion, blood glucose levels, eGFR, and others, were not obtained, which may lead to recall and information biases. Future multicenter studies with larger cohorts and inclusion of short-term glycemic markers or continuous glucose monitoring are recommended to validate and expand upon these findings. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1